|AHFS/Drugs.com||International Drug Names|
|ATC code||C07AB06 (WHO)|
|Chemical and physical data|
|Molar mass||345.43 g/mol|
|3D model (Jmol)||Interactive image|
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. It was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?" As of 2016 it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.
- Frishman, WH; Goldberg, RJ; Benfield, P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.". Drugs. 35 (1): 1–21. PMID 2894292.
- Vaughan Williams, EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.". Journal of clinical pharmacology. 27 (7): 450–60. PMID 2888789.
- McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia. (3rd ed. ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563.
- "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989.
- Wong, GW; Boyda, HN; Wright, JM (10 March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.". The Cochrane database of systematic reviews. 3: CD007451. PMID 26961574.